Selincro

L’alcool correspond au terme utilise pour designer l’ethanol. Si le produit est connu pour ses proprietes desinfectantes, a un… Expand

The opioid antagonist nalmefene (selincro®) was approved for alcohol‐related disorders by the European Medicines Agency in 2013… Expand

AIMS To characterize a contemporaneous cohort of UK general practice patients with alcohol use disorder and describe their… Expand

Introduction Nalmefene (NMF – SELINCRO®), a drug for alcohol withdrawal management (AWM), is both a partial agonist and an… Expand

Case 1 A 43-year-old man was brought by ambulance to the emergency department (ED) with severe agitation and clinical signs of… Expand

Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of… Expand

Both Glasgow and medical school were hard drinking gigs. I enjoy alcohol and drink it for its psychoactive effect rather than for… Expand

The opioid system modulator nalmefene (Selincro®) is the first pharmacological therapy to be approved in the EU to reduce alcohol… Expand

Nalmefene (Selincro) has been recommended to help people reduce their dependence on alcohol, in final draft guidance from the… Expand

The burden of morbidity and mortality resulting from alcohol dependence is high. World Health Organization (WHO) figures suggest… Expand